#	Pagina
attuale pagina	/open-h2020/projects/220033/index.html

Opendata, web and dolomites

LAA-START SIGNED

Left Atrial Appendage Electrical Isolation via Bio-photonic Optical Confirmation to Treat Persistent Atrial Fibrillation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

LAA-START project word cloud

Explore the words cloud of the LAA-START project. It provides you a very rough idea of what is the project "LAA-START" about.

13 wasted 2020 muscle germany doubles left clots fitting caused implants clinical fibrillation patients atrial approximately 30 pulses invasive 5bn data works fda redo catheter healthcare flow causing paf medical line heartbeat certification tissue incapable million 72 heart resistant surgical health aurigen fti symptomatic italy billion appendage financially abnormal medication implant initial first blood hours total isolation opening persistent laa efficacy risk ablation filter markets ce fit france market uk therapy too isolates af destroys irregular treating human surgery arrhythmia shut cardiac opportunity services stroke safety contraction regulatory doubled procedure electrical permanently rates classified minimally q3 device mechanically stream shot occlusion prevent electrically complete amounting entering enter time least

Project "LAA-START" data sheet

The following table provides information about the project.

Coordinator	AURIGEN MEDICAL LIMITED Organization address address: 18 CHURCHWELL SQUARE city: DUBLIN postcode: DUBLIN 13 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Total cost	5˙012˙590 €
EC max contribution	2˙999˙998 € (60%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-EIC-FTI-2018-2020
Funding Scheme	IA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2020-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	AURIGEN MEDICAL LIMITED AURIGEN MEDICAL LIMITED Organization address address: 18 CHURCHWELL SQUARE city: DUBLIN postcode: DUBLIN 13 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	coordinator	1˙115˙458.00
2	TELEFLEX MEDICAL EUROPE LIMITED TELEFLEX MEDICAL EUROPE LIMITED Organization address address: IDA BUSINESS AND TECHNOLOGY PARK, DUBLIN ROAD city: ATHLONE CO. WESTMEATH postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (ATHLONE CO. WESTMEATH)	participant	953˙470.00
3	UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK Organization address address: WESTERN ROAD city: Cork postcode: T12 YN60 website: www.ucc.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (Cork)	participant	516˙948.00
4	MEDIBRANE LTD MEDIBRANE LTD Organization address address: 23 HAMELACHA ST city: ROSH HAAYIN postcode: 4809173 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (ROSH HAAYIN)	participant	334˙600.00
5	CESKE VYSOKE UCENI TECHNICKE V PRAZE CESKE VYSOKE UCENI TECHNICKE V PRAZE Organization address address: JUGOSLAVSKYCH PARTYZANU 1580/3 city: PRAHA postcode: 160 00 website: www.cvut.cz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (PRAHA)	participant	79˙522.00

Map

Project objective

Atrial Fibrillation (AF) is an irregular heartbeat caused by abnormal electrical activity in the heart, that can lead to blood clots with high risk of stroke and heart failure. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF), they are highly symptomatic and medication resistant. Surgical electrical therapy (catheter ablation) destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients. AuriGen Medical have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. This multi-partner FTI project will complete product development in line with the regulatory development pathway for medical devices for first in human safety and efficacy clinical studies required for CE certification and contributing to FDA clinical data requirements. The total market opportunity is $5bn/yr market opportunity across the EU and US. AuriGen will enter the market directly in the initial target European markets (Germany, France, Italy and UK) during Q3 2020.

Deliverables

List of deliverables.
Clinical Affairs Director Appointed	Other	2020-04-02 09:09:54
Biostatistician Appointed	Other	2020-04-02 09:10:11
Manufacturing Engineer Appointed	Other	2020-04-02 09:10:03

Take a look to the deliverables list in detail: detailed list of LAA-START deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LAA-START" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LAA-START" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

PATH-TOX (2018)

Artificial Intelligence to transform Drug and Chemical safety testing

Read More

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More

De-RISC (2019)

De-RISC: Dependable Real-time Infrastructure for Safety-critical Computer

Read More